Biomarker Analysis Services for Retinal Degeneration
Ace Therapeutics offers specialized biomarker analysis services dedicated exclusively to drug discovery and preclinical development for retinal degeneration research. Our comprehensive biomarker panel is designed to provide deep insights into the molecular and cellular mechanisms underlying retinal degeneration, supporting therapeutic innovation and advancing the understanding of disease pathophysiology. Please note that our services are strictly focused on research and preclinical applications, and do not include clinical diagnostic services.
Effective therapeutic intervention for retinal degeneration begins with the robust discovery and identification of relevant biomarkers. Ace Therapeutics employs systematic biomarker discovery services that enable the identification of molecular signatures associated with retinal degeneration. Our approach integrates high-throughput screening and rigorous validation steps, ensuring that candidate biomarkers are reproducibly associated with disease-relevant pathways. Through iterative screening, selection, and verification, we provide a strong foundation for downstream drug development efforts.
Multi Omics: Our multi-omics approach leverages advanced genomics, transcriptomics, proteomics, and metabolomics technologies to enable a holistic study of biological systems involved in retinal degeneration. By integrating data across DNA, RNA, protein, and metabolite levels, we identify and characterize biomarkers that reflect the complexity of retinal disease pathways, including phototransduction, inflammation, and cell survival mechanisms. This comprehensive strategy enables the elucidation of molecular events driving retinal degeneration and supports the identification of novel therapeutic targets.
Candidate Validation: Candidate biomarker validation at Ace Therapeutics involves a suite of experimental and computational strategies to confirm association with retinal degeneration pathophysiology. Preliminary screening includes quantitative and qualitative analyses in relevant preclinical models and sample types. Promising candidates are prioritized based on criteria such as specificity to retinal tissues, reproducibility of detection, biological relevance to disease mechanisms, and amenability to assay development. This process ensures that only the most informative and actionable candidates advance through the research pipeline.
Diverse Technological Platforms: We offer custom assay development tailored to the unique requirements of each biomarker and project. Our technological platforms include immunoassays (ELISA, chemiluminescent, multiplex), mass spectrometry (LC-MS/MS), flow cytometry, molecular diagnostics (PCR, qPCR, digital PCR), and advanced histopathology and imaging modalities. Each platform is adapted to maximize sensitivity, specificity, and throughput for retinal degeneration research applications.
Immunoassays: We develop and optimize ELISA, chemiluminescent, and multiplex immunoassays for quantitative and qualitative detection of protein biomarkers relevant to retinal degeneration.
Mass Spectrometry: Our LC-MS/MS capabilities enable high-sensitivity, high-specificity quantification and characterization of proteins, peptides, and metabolites in complex biological matrices.
Flow Cytometry: We utilize flow cytometry for multiparametric analysis of cell populations, surface markers, and intracellular proteins in retinal tissue and cell-based models.
Molecular Diagnostics: We employ PCR, qPCR, and digital PCR technologies for precise detection and quantification of gene targets and variants associated with retinal degeneration.
Histopathology And Imaging: Advanced histological staining, immunohistochemistry, and high-resolution imaging are used for spatial localization and morphological assessment of biomarkers in retinal tissues.
Rigorous Method Validation: All analytical methods developed at Ace Therapeutics undergo rigorous validation in accordance with relevant research guidelines. Performance characteristics evaluated include sensitivity, specificity, linearity, accuracy, precision, and reproducibility. Robust quality control measures are implemented throughout the process to ensure data integrity and reliability, supporting the generation of actionable research insights.
Our platforms support quantitative analysis of biomarker levels in diverse sample types, enabling precise measurement of changes associated with retinal degeneration. This capability supports pharmacodynamic studies, mechanism-of-action research, and the evaluation of therapeutic efficacy in preclinical models.
Sample Analysis: We handle a wide range of sample types, including retinal tissue, blood, ocular fluids, and cell-based models. Standardized protocols are employed for sample preparation, processing, and analysis to ensure consistency and reproducibility. Stringent quality control procedures are in place to monitor sample integrity and analytical performance at every stage.
High Throughput Capabilities: Ace Therapeutics utilizes multiplexed analytical platforms and automated workflows to enable high-throughput biomarker analysis. This approach increases efficiency, reduces turnaround times, and conserves valuable samples—critical advantages for large-scale preclinical studies and exploratory research.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| interleukin 1 beta (IL1B) | Interleukin 1 beta (IL1B) is a pro-inflammatory cytokine produced primarily by activated macrophages, monocytes, and dendritic cells. It plays a central role in the regulation of immune and inflammatory responses. IL1B is synthesized as an inactive precursor (pro-IL1B) and is cleaved by caspase-1 to generate the active form. Upon secretion, IL1B binds to the interleukin-1 receptor (IL-1R) on target cells, triggering intracellular signaling cascades that lead to the expression of various inflammatory mediators, including additional cytokines, chemokines, and adhesion molecules. These actions contribute to the recruitment and activation of immune cells, fever induction, and modulation of cell proliferation, differentiation, and apoptosis. | IL1B levels are measured in various biological fluids, such as blood, synovial fluid, and cerebrospinal fluid, to assess the presence and extent of inflammation. Elevated IL1B concentrations have been reported in a range of inflammatory and autoimmune conditions, including rheumatoid arthritis, sepsis, inflammatory bowel disease, and certain infectious diseases. Measurement of IL1B is used in research and clinical contexts to monitor inflammatory status, evaluate disease activity, and study the effects of anti-inflammatory therapies. |
| phosphodiesterase 6B (PDE6B) | Phosphodiesterase 6B (PDE6B) encodes the beta subunit of the cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase enzyme found primarily in rod photoreceptor cells of the retina. This enzyme plays a critical role in the phototransduction cascade, which is the process by which light is converted into electrical signals in the retina. Specifically, PDE6B hydrolyzes cGMP to 5'-GMP, leading to the closure of cGMP-gated ion channels, hyperpolarization of the photoreceptor cell membrane, and subsequent transmission of visual signals to the brain. Proper function of PDE6B is essential for normal visual signal processing in rod cells. | Mutations in the PDE6B gene have been associated with inherited retinal degenerative diseases, most notably autosomal recessive retinitis pigmentosa (RP) and congenital stationary night blindness. Genetic testing for variants in PDE6B can be used to aid in the molecular diagnosis of these conditions, facilitate carrier detection, and inform prognosis. The identification of PDE6B mutations is also relevant in the context of clinical trials and gene therapy research targeting retinal dystrophies. |
| retinoid isomerohydrolase RPE65 (RPE65) | Retinoid isomerohydrolase RPE65 (RPE65) is a crucial enzyme in the visual cycle, specifically expressed in the retinal pigment epithelium (RPE). RPE65 catalyzes the isomerization of all-trans-retinyl esters to 11-cis-retinol, a key step in the regeneration of 11-cis-retinal, the chromophore required for phototransduction in rod and cone photoreceptors. This process enables the continuous conversion of light into visual signals. Mutations in the RPE65 gene disrupt this pathway, leading to impaired visual function and are associated with inherited retinal dystrophies such as Leber congenital amaurosis and retinitis pigmentosa. | RPE65 serves as a molecular marker for retinal pigment epithelium cells due to its tissue-specific expression. Measurement of RPE65 gene or protein levels can assist in the identification and characterization of RPE cells in research and clinical samples. Additionally, detection of pathogenic variants in RPE65 is used in the molecular diagnosis of certain inherited retinal diseases, aiding in patient stratification for gene therapy and other targeted interventions. |
| rhodopsin (RHO) | Rhodopsin (RHO) is a light-sensitive G protein-coupled receptor found in the rod photoreceptor cells of the retina. It plays a central role in the visual phototransduction pathway. Upon absorption of photons, rhodopsin undergoes a conformational change, activating the associated G protein transducin, which initiates a signaling cascade that ultimately leads to hyperpolarization of the photoreceptor cell and transmission of visual information to the brain. Rhodopsin is essential for scotopic (low-light) vision and is composed of the apoprotein opsin bound to the chromophore 11-cis-retinal. | Rhodopsin is utilized as a biomarker in the context of retinal diseases, particularly inherited retinal degenerations such as retinitis pigmentosa. Mutations in the RHO gene are among the most common causes of autosomal dominant retinitis pigmentosa. Detection of RHO gene mutations or abnormal rhodopsin protein expression can assist in the molecular diagnosis and genetic characterization of these disorders. Additionally, rhodopsin levels and localization are assessed in research and clinical studies to evaluate retinal health and the progression of degenerative retinal conditions. |
| usherin (USH2A) | Usherin, encoded by the USH2A gene, is a large transmembrane protein primarily expressed in the retina and inner ear. It is a component of the extracellular matrix and is involved in the development and maintenance of photoreceptor cells in the retina and hair cells in the cochlea. Usherin plays a critical role in cell adhesion, structural integrity, and signaling processes essential for sensory cell function. Mutations in USH2A are associated with Usher syndrome type II and non-syndromic retinitis pigmentosa, leading to progressive vision and hearing loss. | USH2A gene variants are used in molecular genetic testing to aid in the diagnosis of Usher syndrome type II and certain forms of autosomal recessive retinitis pigmentosa. Detection of pathogenic mutations in USH2A can assist in confirming clinical diagnosis, informing prognosis, and facilitating genetic counseling for affected individuals and their families. |
Explore Research Opportunities with Ace Therapeutics. Our biomarker research services provide advanced capabilities for the discovery, characterization, and analysis of molecular targets relevant to retinal degeneration, supporting preclinical drug discovery and development. Please note that all biomarkers discussed are research targets only; we do not claim any of these biomarkers as validated or mandatory for any application. Our services are strictly exploratory in nature and focused on preclinical research stages, maintaining the highest standards of scientific objectivity.
We invite you to connect with Ace Therapeutics to discuss collaborative opportunities in retinal degeneration biomarker research. Our focus is on exploratory, preclinical research and scientific exchange—let’s work together to advance understanding and innovation in this field.
Make Order
Experimental Scheme
Implementation
Conclusion
